
Kurt Fernstrom
Examiner (ID: 5518, Phone: (571)272-4422 , Office: P/3711 )
Most Active Art Unit | 3711 |
Art Unit(s) | 3714, 3712, 3715, 3711 |
Total Applications | 2669 |
Issued Applications | 1756 |
Pending Applications | 157 |
Abandoned Applications | 755 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18339973
[patent_doc_number] => 20230131922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => LONG-ACTING POLYPEPTIDE COMPOSITION FOR TREATING ATRIAL FIBRILLATION AND ITS APPLICATION
[patent_app_type] => utility
[patent_app_number] => 17/931117
[patent_app_country] => US
[patent_app_date] => 2022-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2030
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17931117
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/931117 | Long-acting polypeptide composition for treating atrial fibrillation and its application | Sep 9, 2022 | Issued |
Array
(
[id] => 18530336
[patent_doc_number] => 20230235406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/903700
[patent_app_country] => US
[patent_app_date] => 2022-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17903700
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/903700 | IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE | Sep 5, 2022 | |
Array
(
[id] => 18361105
[patent_doc_number] => 20230142696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => Reconstituted HDL Formulation
[patent_app_type] => utility
[patent_app_number] => 17/902580
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6566
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17902580
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/902580 | Reconstituted HDL formulation | Sep 1, 2022 | Issued |
Array
(
[id] => 18449618
[patent_doc_number] => 20230190894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/821713
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14119
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821713
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/821713 | METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINS | Aug 22, 2022 | Pending |
Array
(
[id] => 18018170
[patent_doc_number] => 20220369669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => METHOD FOR PRODUCING HYDROLYSED KERATINACEOUS MATERIAL
[patent_app_type] => utility
[patent_app_number] => 17/879291
[patent_app_country] => US
[patent_app_date] => 2022-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7584
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17879291
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/879291 | METHOD FOR PRODUCING HYDROLYSED KERATINACEOUS MATERIAL | Aug 1, 2022 | Pending |
Array
(
[id] => 18321902
[patent_doc_number] => 20230120030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => Long-Acting Adrenomedullin Derivatives
[patent_app_type] => utility
[patent_app_number] => 17/816173
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23030
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816173
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/816173 | Long-Acting Adrenomedullin Derivatives | Jul 28, 2022 | Abandoned |
Array
(
[id] => 18286300
[patent_doc_number] => 20230101772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => PEPTIDES AND METHODS FOR TREATING DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/810513
[patent_app_country] => US
[patent_app_date] => 2022-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810513
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/810513 | PEPTIDES AND METHODS FOR TREATING DISEASE | Jun 30, 2022 | Pending |
Array
(
[id] => 17897050
[patent_doc_number] => 20220306712
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => METHODS OF TREATMENT USING MUTANT FGF-21 PEPTIDE CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/842143
[patent_app_country] => US
[patent_app_date] => 2022-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 219
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842143
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842143 | Methods of treatment using mutant FGF-21 peptide conjugates | Jun 15, 2022 | Issued |
Array
(
[id] => 17958659
[patent_doc_number] => 20220339239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY
[patent_app_type] => utility
[patent_app_number] => 17/831887
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16017
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/831887 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | Jun 2, 2022 | Pending |
Array
(
[id] => 18124145
[patent_doc_number] => 20230009757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => COMBINATION THERAPY FOR C3 INHIBITION
[patent_app_type] => utility
[patent_app_number] => 17/719074
[patent_app_country] => US
[patent_app_date] => 2022-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 105502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719074
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/719074 | COMBINATION THERAPY FOR C3 INHIBITION | Apr 11, 2022 | Pending |
Array
(
[id] => 17850550
[patent_doc_number] => 20220280591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => Use For JNK Inhibitor Molecules For Treatment Of Various Diseases
[patent_app_type] => utility
[patent_app_number] => 17/719068
[patent_app_country] => US
[patent_app_date] => 2022-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719068
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/719068 | Use For JNK Inhibitor Molecules For Treatment Of Various Diseases | Apr 11, 2022 | Abandoned |
Array
(
[id] => 17776563
[patent_doc_number] => 20220242912
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => THERAPEUTIC PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/717982
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51355
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717982
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/717982 | Therapeutic peptides | Apr 10, 2022 | Issued |
Array
(
[id] => 18036587
[patent_doc_number] => 20220380802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/713809
[patent_app_country] => US
[patent_app_date] => 2022-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17713809
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/713809 | CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER | Apr 4, 2022 | Pending |
Array
(
[id] => 18004956
[patent_doc_number] => 20220363722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => Peptides for the Treatment of COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/699792
[patent_app_country] => US
[patent_app_date] => 2022-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699792
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/699792 | Peptides for the treatment of COVID-19 | Mar 20, 2022 | Issued |
Array
(
[id] => 17685901
[patent_doc_number] => 20220193193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2
[patent_app_type] => utility
[patent_app_number] => 17/682454
[patent_app_country] => US
[patent_app_date] => 2022-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58951
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682454
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/682454 | METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2 | Feb 27, 2022 | Pending |
Array
(
[id] => 18642361
[patent_doc_number] => 11766414
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-26
[patent_title] => Compositions, delivery systems, and methods useful in tumor therapy
[patent_app_type] => utility
[patent_app_number] => 17/577270
[patent_app_country] => US
[patent_app_date] => 2022-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 52
[patent_figures_cnt] => 64
[patent_no_of_words] => 40715
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 240
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17577270
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/577270 | Compositions, delivery systems, and methods useful in tumor therapy | Jan 16, 2022 | Issued |
Array
(
[id] => 18871230
[patent_doc_number] => 11859018
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Peptoid-based chelating ligands for selective metal chelation
[patent_app_type] => utility
[patent_app_number] => 17/576577
[patent_app_country] => US
[patent_app_date] => 2022-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 10956
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576577
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/576577 | Peptoid-based chelating ligands for selective metal chelation | Jan 13, 2022 | Issued |
Array
(
[id] => 17546706
[patent_doc_number] => 20220118047
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => METHOD OF TREATING GLIOBLASTOMA
[patent_app_type] => utility
[patent_app_number] => 17/563532
[patent_app_country] => US
[patent_app_date] => 2021-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12207
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17563532
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/563532 | METHOD OF TREATING GLIOBLASTOMA | Dec 27, 2021 | Pending |
Array
(
[id] => 19439982
[patent_doc_number] => 12090208
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Peptide drug improvement using vitamin B
[patent_app_type] => utility
[patent_app_number] => 17/558920
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 3824
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/558920 | Peptide drug improvement using vitamin B | Dec 21, 2021 | Issued |
Array
(
[id] => 18273713
[patent_doc_number] => 11612634
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-28
[patent_title] => Pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance
[patent_app_type] => utility
[patent_app_number] => 17/548717
[patent_app_country] => US
[patent_app_date] => 2021-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 47
[patent_no_of_words] => 12417
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548717
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/548717 | Pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance | Dec 12, 2021 | Issued |